- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NCI to Begin Search for a New Director
Harold Varmus, MD, who has led the National Cancer Institute at the National Institutes of Health for nearly 5 years, announced today that he will step down from his post, effective March 31, 2015.
Harold Varmus, MD, who has led the National Cancer Institute (NCI) at the National Institutes of Health (NIH) for nearly 5years, announced today that he will step down from his post, effective March 31, 2015.
“It has been our great fortune to have Harold at the helm of the NCI,” said NIH Director Francis S. Collins, MD, PhD, “His breadth and depth of expertise in biomedical research is unparalleled, and he’s been a tremendous colleague to me and invaluable to the agency.” Douglas Lowy, MD, who currently serves as the Deputy Director, will become acting director for NCI beginning April 1, 2015. Dr Lowy, a long-time NCI intramural researcher, received the National Medal of Technology and Innovation from President Obama in 2014 for his research that led to the development of the human papillomavirus (HPV) vaccine.
Read the complete news release by the NIH: http://1.usa.gov/1FYgj3i
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
